HC Wainwright Reaffirms “Buy” Rating for Coya Therapeutics (NASDAQ:COYA)

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They presently have a $18.00 price target on the stock. HC Wainwright’s price objective suggests a potential upside of 148.28% from the stock’s current price.

Separately, Chardan Capital restated a “buy” rating and issued a $14.00 target price on shares of Coya Therapeutics in a research note on Thursday, November 7th.

Coya Therapeutics Trading Down 1.1 %

COYA stock opened at $7.25 on Monday. The stock’s 50 day simple moving average is $7.05 and its 200 day simple moving average is $7.02. Coya Therapeutics has a 12-month low of $4.75 and a 12-month high of $10.69. The firm has a market cap of $121.13 million, a P/E ratio of -11.15 and a beta of 0.46.

Coya Therapeutics (NASDAQ:COYA) last issued its earnings results on Wednesday, November 6th. The company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.15. On average, research analysts forecast that Coya Therapeutics will post -1.27 EPS for the current fiscal year.

Insider Transactions at Coya Therapeutics

In other news, CEO Arun Swaminathan acquired 5,000 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The shares were purchased at an average cost of $7.34 per share, for a total transaction of $36,700.00. Following the transaction, the chief executive officer now directly owns 5,000 shares in the company, valued at $36,700. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 12.00% of the company’s stock.

Institutional Investors Weigh In On Coya Therapeutics

Hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. increased its position in Coya Therapeutics by 772.3% in the 1st quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock valued at $8,407,000 after acquiring an additional 750,338 shares during the period. Renaissance Technologies LLC acquired a new position in shares of Coya Therapeutics during the second quarter valued at $101,000. GHP Investment Advisors Inc. bought a new stake in shares of Coya Therapeutics during the third quarter valued at about $169,000. Finally, Gilbert & Cook Inc. acquired a new stake in Coya Therapeutics in the second quarter worth about $61,000. Institutional investors own 39.75% of the company’s stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.